| P50 | author | Henrik Zetterberg | Q6252048 |
| | Inger van Steenoven | Q59846531 |
| | Elisabet Londos | Q66724780 |
| | Brit Mollenhauer | Q30500738 |
| | Dag Aarsland | Q41599688 |
| P2093 | author name string | Frédéric Blanc | |
| | Carla Abdelnour | |
| | Mercè Boada | |
| | Milica G Kramberger | |
| | Bjørn Auestad | |
| | European DLB Consortium | |
| P2860 | cites work | Montreal Cognitive Assessment and Mini-Mental State Examination performance in patients with mild-to-moderate dementia with Lewy bodies, Alzheimer's disease, and normal participants in Taiwan | Q44075273 |
| | Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study | Q46522469 |
| | Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies | Q47237010 |
| | The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean? | Q48315717 |
| | Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias | Q48616026 |
| | Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies | Q49168413 |
| | Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. | Q50637977 |
| | The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. | Q50675339 |
| | CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. | Q51050295 |
| | Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. | Q53305247 |
| | Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia | Q58478217 |
| | “Mini-mental state” | Q25938989 |
| | CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease | Q27304608 |
| | Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium | Q29614409 |
| | Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease | Q33822641 |
| | Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. | Q33864626 |
| | CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease | Q34140382 |
| | Lewy body dementias. | Q34502646 |
| | Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both | Q34806323 |
| | CSF biomarkers and clinical progression of Parkinson disease | Q35106542 |
| | Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders | Q35597118 |
| | Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline | Q35840610 |
| | Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients | Q36120659 |
| | CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease | Q36535217 |
| | MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study | Q36763084 |
| | Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment | Q37897602 |
| | Amyloid-β and τ biomarkers in Parkinson's disease-dementia | Q37901874 |
| | Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis | Q38211809 |
| | Imaging the role of amyloid in PD dementia and dementia with Lewy bodies | Q38228098 |
| | Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments | Q38543125 |
| | Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders | Q38603309 |
| | Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease | Q38641189 |
| | Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort | Q39675579 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| | cerebrospinal fluid | Q54196 |
| | biomarker | Q864574 |
| P304 | page(s) | 1203-1208 | |
| P577 | publication date | 2016-06-14 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia | |
| P478 | volume | 31 | |